The stock of Precigen Inc (NASDAQ: PGEN) has increased by 11.68 when compared to last closing price of 1.37. Despite this, the company has experienced a 9.29% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-16 that – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection – – There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will team up again with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to co-host the annual RRP Awareness Day on June 11, 2025.
Is It Worth Investing in Precigen Inc (NASDAQ: PGEN) Right Now?
The 36-month beta value for PGEN is at 1.78. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PGEN is 162.39M, and currently, shorts hold a 14.72% of that float. The average trading volume for PGEN on April 23, 2025 was 1.76M shares.
PGEN’s Market Performance
PGEN’s stock has seen a 9.29% increase for the week, with a -15.47% drop in the past month and a 29.66% gain in the past quarter. The volatility ratio for the week is 7.32%, and the volatility levels for the past 30 days are at 10.27% for Precigen Inc The simple moving average for the last 20 days is 6.97% for PGEN stock, with a simple moving average of 24.49% for the last 200 days.
Analysts’ Opinion of PGEN
Cantor Fitzgerald gave a rating of “Overweight” to PGEN, setting the target price at $7 in the report published on November 18th of the previous year.
PGEN Trading at -8.10% from the 50-Day Moving Average
After a stumble in the market that brought PGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.49% of loss for the given period.
Volatility was left at 10.27%, however, over the last 30 days, the volatility rate increased by 7.32%, as shares sank -15.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.00% lower at present.
During the last 5 trading sessions, PGEN rose by +9.29%, which changed the moving average for the period of 200-days by +4.08% in comparison to the 20-day moving average, which settled at $1.4303. In addition, Precigen Inc saw 36.61% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PGEN starting from Perez Jeffrey Thomas, who purchase 58,823 shares at the price of $0.85 back on Aug 09 ’24. After this action, Perez Jeffrey Thomas now owns 743,097 shares of Precigen Inc, valued at $50,000 using the latest closing price.
KIRK RANDAL J, the Director of Precigen Inc, purchase 23,529,411 shares at $0.85 during a trade that took place back on Aug 09 ’24, which means that KIRK RANDAL J is holding 64,547,214 shares at $19,999,999 based on the most recent closing price.
Stock Fundamentals for PGEN
Current profitability levels for the company are sitting at:
- -34.4 for the present operating margin
- -0.29 for the gross margin
The net margin for Precigen Inc stands at -32.16. The total capital return value is set at -1.09. Equity return is now at value -136.30, with -82.32 for asset returns.
Based on Precigen Inc (PGEN), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -12.39. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -22505.33.
Currently, EBITDA for the company is -123.5 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 108.5. The receivables turnover for the company is 3.37for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.76.
Conclusion
In conclusion, Precigen Inc (PGEN) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
